BackgroundThe SAMe-TT2R2 score was developed to predict which
patients on oral anticoagulation with vitamin K antagonists (VKAs) will
reach an adequate time in therapeutic range (TTR) (> 65%-70%). Studies
have reported a relationship between this score and the occurrence of
adverse events.ObjectiveTo describe the TTR according to the score, in addition to relating the score
obtained with the occurrence of adverse events in patients with nonvalvular
atrial fibrillation (AF) on oral anticoagulation with VKAs.MethodsRetrospective cohort study including patients with nonvalvular AF attending
an outpatient anticoagulation clinic of a tertiary hospital. Visits to the
outpatient clinic and emergency, as well as hospital admissions to the
institution, during 2014 were evaluated. The TTR was calculated through the
Rosendaal´s method.ResultsWe analyzed 263 patients (median TTR, 62.5%). The low-risk group (score 0-1)
had a better median TTR as compared with the high-risk group (score ≥
2): 69.2% vs. 56.3%, p = 0.002. Similarly, the percentage of patients with
TTR ≥ 60%, 65% or 70% was higher in the low-risk group (p < 0.001,
p = 0.001 and p = 0.003, respectively). The high-risk group had a higher
percentage of adverse events (11.2% vs. 7.2%), although not significant (p =
0.369).ConclusionsThe SAMe-TT2R2 score proved to be effective to predict
patients with a better TTR, but was not associated with adverse events.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.